Wells Fargo & Company Fusion Pharmaceuticals Inc. Call Options Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding FUSN
# of Institutions
141Shares Held
67.3MCall Options Held
1.36MPut Options Held
3.97M-
Federated Hermes, Inc. Pittsburgh, PA10.8MShares$00.54% of portfolio
-
Perceptive Advisors LLC New York, NY6.83MShares$03.05% of portfolio
-
Avidity Partners Management LP Dallas, TX6.5MShares$05.35% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.4MShares$02.82% of portfolio
-
Fil LTD Hamilton, D04.19MShares$00.09% of portfolio
About Fusion Pharmaceuticals Inc.
- Ticker FUSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,390,500
- Description
- Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order ...